Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
FID-007 + cetuximab
- Development stage
- Unknown
- Lead developer
- Fulgent Pharma
- Modality
- Nanoparticles → Drug Delivery Systems, Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous
01
Overview
FID-007 + cetuximab is an experimental combination therapy for cancer, specifically investigated for advanced, recurrent, or metastatic head and neck squamous cell carcinoma (HNSCC). FID-007 is a nanoencapsulated formulation of paclitaxel, a microtubule inhibitor, where paclitaxel is encapsulated with a polyethyloxazoline (PEOX) polymer using nano-drug delivery technology to improve pharmacokinetics and tumor targeting while reducing toxicity. Cetuximab is a chimeric monoclonal antibody that targets the epidermal growth factor receptor (EGFR), inhibiting downstream signaling, cell proliferation, and survival. The intention behind combining FID-007 with cetuximab is to synergize the enhanced cytotoxic and possible immunomodulatory effects of paclitaxel with targeted inhibition of EGFR-driven tumor growth. This combination is currently being studied in a phase 2 clinical trial for head and neck squamous cell carcinoma[1][5].
- Other names
- paclitaxel in polyethyloxazoline polymer + cetuximabnanoencapsulated paclitaxel FID-007 + cetuximab
02
Targets
EGFR T790M (Epidermal growth factor receptor T790M mutant)TUBB (Tubulin (alpha and beta subunits))
Beyond the preview
Go deeper on FID-007 + cetuximab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on FID-007 + cetuximab.